1-{3-[4-(4-oxocyclohexyl)phenoxy]propyl}piperidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-{3-[4-(4-oxocyclohexyl)phenoxy]propyl}piperidine
• 英文别名: 1-{3-[4-(4-Oxocyclohexyl)phenoxy]propyl}-piperidine；4-[4-(3-piperidin-1-ylpropoxy)phenyl]cyclohexan-1-one
• 化学式: C₂₀H₂₉NO₂
• 分子量: 315.456
• InChiKey: PAWKQFHVEWLZGA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-{3-[4-(4-oxocyclohexyl)phenoxy]propyl}piperidine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Novel and highly potent histamine H3 receptor ligands. Part 3: An alcohol function to improve the pharmacokinetic profile

  摘要：

  Synthesis and biological evaluation of potent histamine H-3 receptor antagonists incorporating a hydroxyl function are described. Compounds in this series exhibited nanomolar binding affinities for human receptor, illustrating a new possible component for the H-3 pharmacophore. As demonstrated with compound BP1.4160 (cyclohexanol 19), the introduction of an alcohol function counter-intuitively allowed to reach high in vivo efficiency and favorable pharmacokinetic profile with reduced half-life. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.118
• 作为产物：
  描述：

  4-(4-羟基苯基)环己酮 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 1-{3-[4-(4-oxocyclohexyl)phenoxy]propyl}piperidine
  参考文献：
  名称：

  Novel and highly potent histamine H3 receptor ligands. Part 2: Exploring the cyclohexylamine-based series

  摘要：

  Synthesis and biological evaluation of novel and potent cyclohexylamine-based histamine H3 receptor inverse agonists are described. Compounds in this newly identified series exhibited subnanomolar binding affinities for human receptor and no significant interaction with hERG channel. One derivative (10t) demonstrated enhanced in vivo efficiency and preferential brain distribution, both properties suitable for potential clinical evaluation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.102

文献信息

• Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
  申请人：BIOPROJET

  公开号：EP1717234A1

  公开（公告）日：2006-11-02

  The present patent application concerns compounds of formula (I), with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

  本专利申请涉及公式（I）的化合物，其中R1和R2与它们所连接的氮原子一起形成一个单环或双环饱和氮含环；它们的制备以及它们作为H3受体配体用于治疗例如阿尔茨海默病等中枢神经系统疾病。
• NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Bertrand Isabelle

  公开号：US20090111808A1

  公开（公告）日：2009-04-30

  The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

  本专利申请涉及式(I)的化合物，其中R1和R2与它们所连接的氮原子结合形成单环或双环饱和含氮环; 它们的制备及其用作H3受体配体，用于治疗例如阿尔茨海默病等中枢神经系统疾病。
• Histamine H3-receptor ligands and their therapeutic applications
  申请人：Bioprojet

  公开号：US08076329B2

  公开（公告）日：2011-12-13

  The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

  本专利申请涉及公式（I）化合物，其中R1和R2与它们附着的氮原子一起形成单环或双环饱和含氮环；它们的制备以及它们作为H3受体配体用于治疗例如阿尔茨海默病等中枢神经系统疾病。
• Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity
  作者：Nicolas Levoin、Olivier Labeeuw、Thierry Calmels、Olivia Poupardin-Olivier、Isabelle Berrebi-Bertrand、Jeanne-Marie Lecomte、Jean-Charles Schwartz、Marc Capet

  DOI：10.1016/j.bmcl.2011.07.006

  日期：2011.9

  Pre-clinical investigation of some aryl-piperidinyl ether histamine H3 receptor antagonists revealed a strong hERG binding. To overcome this issue, we have developed a QSAR model specially dedicated to H3 receptor ligands. This model was designed to be directly applicable in medicinal chemistry with no need of molecular modeling. The resulting recursive partitioning trees are robust (80-85% accuracy), but also simple and comprehensible. A novel promising lead emerged from our work and the structure-activity relationships are presented. (C) 2011 Elsevier Ltd. All rights reserved.
• Novel and highly potent histamine H3 receptor ligands. Part 2: Exploring the cyclohexylamine-based series
  作者：Olivier Labeeuw、Nicolas Levoin、Olivia Poupardin-Olivier、Thierry Calmels、Xavier Ligneau、Isabelle Berrebi-Bertrand、Philippe Robert、Jeanne-Marie Lecomte、Jean-Charles Schwartz、Marc Capet

  DOI：10.1016/j.bmcl.2011.06.102

  日期：2011.9

  Synthesis and biological evaluation of novel and potent cyclohexylamine-based histamine H3 receptor inverse agonists are described. Compounds in this newly identified series exhibited subnanomolar binding affinities for human receptor and no significant interaction with hERG channel. One derivative (10t) demonstrated enhanced in vivo efficiency and preferential brain distribution, both properties suitable for potential clinical evaluation. (C) 2011 Elsevier Ltd. All rights reserved.